Company | International Paper Company | Earnings Date | July 30, 2026 (Pre-Market) |
Ticker | IP (NYSE) | Prepared Date | July 29, 2026 |
Reporting Period | Q2 2026 (June 30, 2026) | Sector ETF | IYM (Materials) |
Key Takeaway: The setup is a low bar with a potential beat on EBITDA — management pre-disclosed Q2 adjusted EBITDA of $520–$570M (midpoint $545M) vs. consensus of ~$539M, effectively anchoring expectations; the bigger swing factor is whether the H2 recovery bridge — driven by $70/ton of published price increases flowing through in Q3 — is credible enough to re-rate the stock.
Heading into Q2 2026 results, the bar for International Paper is deliberately low: management pre-announced a preliminary, unaudited Q2 adjusted EBITDA range of $520–$570M (midpoint $545M) on July 17, essentially setting the floor for consensus and removing most of the downside surprise risk on the headline number. The consensus EPS estimate of –$0.04 reflects the reality that Q2 is the trough quarter — peak EMEA margin compression (paper cost increases flowing through ahead of box pricing recovery), a heavy maintenance outage schedule including the Riverdale paper machine conversion, and the lingering drag from the February $20/ton price decrease — all of which management explicitly guided for on the April 30 call. Estimate trajectory has been modestly negative (Q2 EPS drifted from –$0.02 to –$0.04 over 60 days) but the EBITDA pre-announcement has stabilized the near-term number. The stock has rallied ~40% since the Q1 print (from $30.42 to ~$44), driven by a sharp re-rating on the back of PKG's Q2 beat and a new $140/ton containerboard price increase announcement, a JPMorgan upgrade to Overweight with a $61 target, and improving sentiment around the H2 pricing recovery thesis — meaning the stock has already priced in a meaningful portion of the good news. The wildcard is the credibility of the H2 2026 EBITDA step-up of ~$650M in North America: if management can demonstrate that the March/April price increases are flowing through as expected and that EMEA margin compression has peaked, the stock could sustain its re-rating; if macro headwinds (diesel, OCC, demand softness) or EMEA execution disappoint again, the rally is vulnerable.
Key Takeaway: Consensus is a low bar heading into Q2 — management pre-announced EBITDA of $520–$570M, bracketing the ~$539M consensus estimate; the bigger swing factor is North America EBITDA (guided $380–$410M) vs. execution on cost-out and volume, while EMEA is expected to be the trough quarter at $150–$170M.
KPI | Q1 2026 Actual | Q2 2025 Actual (Prior Year) | Q2 2026 Consensus Estimate | YoY Change | Q2 2026 Guidance (Mgmt) | Consensus vs. Guidance Midpoint |
Adj. EBITDA — Enterprise ($M) | $677M | $733M | $539M | −26.5% | $520–$570M (mid: $545M) | −1.1% |
Adj. EBITDA — North America ($M) | $477M | $515M | $398M | −22.7% | $380–$410M (mid: $395M) | +0.8% |
Adj. EBITDA — EMEA ($M) | $208M | $194M | $159M | −18.0% | $150–$170M (mid: $160M) | −0.6% |
Net Revenue ($B) | $5.97B | $6.77B | $6.21B | −8.3% | N/A — not provided | N/A |
EPS — Diluted Operating ($/sh) | $0.15 | $0.20 | –$0.03 | NM | N/A — not provided | N/A |
NA Packaging Volume (Kshort ton) | 3,301 | 3,613 | 3,471 | −3.9% | ~+3% YoY (mgmt commentary) | N/A |
EMEA Packaging Volume (Kshort ton) | 1,799 | 1,837 | 1,856 | +1.0% | Favorable sequentially | N/A |
Free Cash Flow ($M) | $94M | $54M | $557M | NM | $300–$500M (FY 2026) | N/A (FY guidance) |
Source: Visible Alpha consensus and actuals. Enterprise EBITDA consensus $539M vs. management pre-announced midpoint of $545M (−1.1% gap). NA EBITDA consensus $398M vs. guidance midpoint $395M (+0.8%). EMEA consensus $159M vs. guidance midpoint $160M (−0.6%). FCF Q2 consensus of $557M appears elevated vs. the FY guidance of $300–$500M and likely reflects timing/modeling differences; FY FCF consensus of $344M is more consistent with guidance.
Quarter | KPI | Reported | Consensus Est. | Surprise % | Result |
Q1 2026 | Adj. EBITDA | $677M | $706M | −4.1% | MISS |
Q1 2026 | Op. EPS | $0.15 | $0.15 | 0.0% | IN-LINE |
Q4 2025 | Adj. EBITDA | $758M | $776M | −2.3% | MISS |
Q4 2025 | Op. EPS | –$0.08 | $0.26 | NM | MISS |
Q3 2025 | Adj. EBITDA | $859M | $933M | −7.9% | MISS |
Q3 2025 | Op. EPS | –$0.43 | $0.46 | NM | MISS |
Q2 2025 | Adj. EBITDA | $733M | $777M | −5.7% | MISS |
Q2 2025 | Op. EPS | $0.20 | $0.39 | −48.7% | MISS |
Q1 2025 | Adj. EBITDA | $769M | $680M | +13.1% | BEAT |
Q1 2025 | Op. EPS | $0.23 | $0.38 | −39.5% | MISS |
Q4 2024 | Adj. EBITDA | $505M | $533M | −5.3% | MISS |
Q4 2024 | Op. EPS | –$0.02 | $0.00 | NM | IN-LINE |
Q3 2024 | Adj. EBITDA | $500M | $429M | +16.5% | BEAT |
Q3 2024 | Op. EPS | $0.44 | $0.25 | +76.0% | BEAT |
Q2 2024 | Adj. EBITDA | $561M | $522M | +7.5% | BEAT |
Q2 2024 | Op. EPS | $0.55 | $0.42 | +30.9% | BEAT |
Pattern: IP has missed EBITDA consensus in 5 of the last 8 quarters (and EPS in 6 of 8), with misses concentrated in the post-DS Smith integration period (Q2 2025 through Q1 2026) as transformation costs and macro headwinds repeatedly exceeded expectations; the Q2 2026 pre-announcement effectively eliminates the downside surprise risk on the headline number, making the H2 guidance commentary the key market-moving variable at this print.
Key Takeaway: Management cut full-year 2026 enterprise EBITDA guidance by ~$300M at the Q1 print (April 30) and subsequently pre-announced Q2 EBITDA of $520–$570M on July 17 — no further formal guidance changes since then; tone has shifted from frustration over execution gaps to cautious optimism around H2 pricing recovery and cost-out execution.
Metric | Initial Guidance (Q1 2026 Earnings Call — Apr 30) | Revised Guidance | Current Consensus | Note |
Q2 2026 Enterprise Adj. EBITDA | $520–$570M (mid: $545M) | Reaffirmed Jul 17 pre-announcement | ~$539M | Pre-announced Jul 17 via press release; preliminary/unaudited; midpoint $545M is ~1% above consensus |
Q2 2026 NA Packaging Adj. EBITDA | $380–$410M (mid: $395M) | — | ~$398M | Consensus in-line with guidance midpoint; heavy outage schedule (2x normal) and Riverdale conversion are key headwinds |
Q2 2026 EMEA Packaging Adj. EBITDA | $150–$170M (mid: $160M) | — | ~$159M | Peak margin compression quarter; paper cost increases flowing through ahead of box pricing recovery (3–6 month lag) |
FY 2026 Enterprise Adj. EBITDA | $3.2–$3.5B (cut from $3.5–$3.7B at Q4 2025) | — | ~$3.23B | Consensus near low end of range; H2 step-up of ~$650M in NA required to achieve midpoint; macro headwinds (diesel, OCC) are key risk |
FY 2026 NA Packaging Adj. EBITDA | $2.35–$2.5B (cut from $2.5–$2.6B) | — | ~$2.41B | Consensus near midpoint; $175M pricing tailwind from Feb/Mar/Apr increases expected to flow through in H2 |
FY 2026 EMEA Packaging Adj. EBITDA | $900M–$1.0B (cut from $1.0–$1.1B) | — | ~$913M | Consensus near low end; H2 EMEA EBITDA guided $540–$620M (vs. ~$360M in H1); energy normalization and margin recovery are key assumptions |
FY 2026 Free Cash Flow | $300–$500M | — | ~$344M | Consensus near low end; dividend coverage requires sustained EBITDA improvement; Norpac acquisition adds CapEx |
2027 Enterprise Adj. EBITDA Target | $5.0B (reaffirmed; cut from $5.5–$6.0B at Q4 2025) | — | ~$4.21B | Consensus ~$800M below management target; market skeptical on EMEA execution and pricing sustainability; full opportunity realization pushed to 2028 |
Key Takeaway: Estimates for Q2 2026 have drifted modestly lower since the Q1 print (EBITDA –$17M, EPS –$0.01) as the pre-announcement anchored the range; FY 2026 EBITDA estimates are essentially flat post-Q1 print, sitting near the low end of guidance, while FY 2027 estimates remain ~$800M below management’s $5B target — the gap represents the market’s skepticism on EMEA execution and pricing durability.
KPI (Period) | Estimate (May 5, 2026 — 5 days post Q1 print) | Current Consensus | Estimate Δ (%) | Initial Guidance (Q1 Call) | Current Guidance | Guidance Δ | Consensus vs. Guidance (%) |
Adj. EBITDA — Enterprise (Q2 2026) | $534M | $539M | +0.9% | $520–$570M | $520–$570M (reaffirmed Jul 17) | Unchanged | −1.1% vs. mid |
Adj. EBITDA — Enterprise (FY 2026) | $3.220B | $3.234B | +0.4% | $3.2–$3.5B | $3.2–$3.5B (unchanged) | Unchanged | −4.9% vs. mid |
Adj. EBITDA — Enterprise (FY 2027) | $4.147B | $4.212B | +1.6% | $5.0B target | $5.0B target (reaffirmed) | Unchanged | −15.8% vs. target |
Net Revenue (Q2 2026) | $6.228B | $6.212B | −0.3% | N/A | N/A | N/A | N/A |
Net Revenue (FY 2026) | $24.797B | $24.901B | +0.4% | N/A | N/A | N/A | N/A |
Op. EPS — Diluted (Q2 2026) | –$0.04 | –$0.03 | Improved | N/A | N/A | N/A | N/A |
Op. EPS — Diluted (FY 2026) | $1.352 | $1.361 | +0.7% | N/A | N/A | N/A | N/A |
Source: Visible Alpha consensus. Baseline as of May 5, 2026 (5 trading days post Q1 2026 earnings on April 30, 2026). Estimates have been remarkably stable since the Q1 print, with the EBITDA pre-announcement on July 17 effectively anchoring Q2 expectations. The key risk/opportunity is in the H2 bridge: consensus FY 2026 EBITDA of $3.23B implies ~$2.16B in H2, requiring a ~$1.08B H2 run-rate vs. ~$1.22B in H1 — management’s $650M NA step-up alone would imply a much stronger H2, suggesting consensus may be conservative if pricing flows through as guided.
Key Takeaway: IP has rallied ~40% since the Q1 print (from $30.42 to ~$44), dramatically outperforming peers PKG (+17%) and AMCR (+21%), driven almost entirely by multiple re-rating and sentiment recovery rather than estimate revisions — the stock was pricing in a worst-case scenario post-Q1 and has partially recovered as the H2 pricing thesis gained credibility via PKG’s strong Q2 and the new $140/ton containerboard price increase announcement.
IP vs. PKG vs. AMCR — Indexed Price Performance Since Q1 2026 Earnings (April 30, 2026). Base = 100. Sector ETF used: IYM (iShares U.S. Basic Materials ETF). Key events marked: UBS downgrade (May 4), Citi/WF PT raises (Jul 9), BofA downgrade (Jul 14), Board changes 8-K (Jul 17), PKG Q2 beat + $140/ton CB price hike (Jul 24), JPM upgrade to Overweight (Jul 28).
IP dropped nearly 10% on April 30 (Q1 earnings day) as the full-year EBITDA guidance cut of ~$300M shocked the market, pushing the stock to multi-year lows near $30. The subsequent recovery has been driven by three catalysts: (1) PKG’s Q2 2026 beat on July 23 and announcement of a new $140/ton containerboard price increase (two tranches of $50 and $90), which validated the North American pricing recovery thesis; (2) JPMorgan’s upgrade to Overweight with a $61 target on July 28, the most bullish call on the Street; and (3) the July 17 EBITDA pre-announcement ($520–$570M) which removed downside tail risk. The stock’s 40% rally since the Q1 print means it has already priced in a meaningful portion of the H2 recovery — at ~$44, IP trades at roughly 13.6x FY 2026 consensus EBITDA of $3.23B on an EV basis, still at a discount to peers but no longer at distressed levels. The key question heading into the print is whether management can provide enough confidence in the H2 bridge to sustain the re-rating.
Key Takeaway: PKG’s Q2 2026 beat (reported July 23) is the most important read-through — it validates the North American containerboard market tightness thesis and the pricing recovery trajectory that underpins IP’s H2 bridge; GPK’s Q1 commentary (May 5) and Wells Fargo conference (June 9) add color on cost inflation and demand resilience that is directly relevant to IP’s Q2 setup.
Key Takeaway: The most important development since the Q1 print is PKG’s Q2 beat and announcement of a new $140/ton containerboard price increase on July 23–24, which directly validates IP’s H2 pricing recovery thesis and triggered a sharp re-rating of IP shares; the JPMorgan upgrade to Overweight ($61 target) on July 28 is the most bullish sell-side call and adds momentum heading into the print.
Key Takeaway: The only notable open-market transaction is a discretionary open-market buy by Director Scott Tozier on May 1, 2026 (10,000 shares at ~$31.50, ~$315K) — a meaningful signal of insider confidence at the post-Q1 lows; all other activity is routine director compensation grants (RSU/stock awards) with no open-market sales.
Name | Title | Transaction Type | Shares / Value | Date | Note |
Tozier, Scott | Director | Open Market Buy | 10,000 shares / ~$315K | May 1, 2026 | Discretionary open-market purchase at post-Q1 lows (~$31.50); no 10b5-1 plan; meaningful signal of insider confidence at the trough |
Beggs, Jamie A. | Director | RSU Award (Compensation) | 10,506 RSUs | May 12, 2026 | Routine annual director compensation grant; not a market signal |
Connor, Christopher M. | Director | RSU Award (Compensation) | 11,414 RSUs | May 12, 2026 | Routine annual director compensation grant; not a market signal |
Dorduncu, Ahmet C. | Director | Stock Award + Tax Withholding Sale | 5,298 shares awarded; 1,186 shares withheld for taxes | May 12, 2026 | Routine compensation; tax withholding sale is obligation-driven, not discretionary |
Gustafsson, Anders | Director | Stock Award (Compensation) | 11,112 shares | May 12, 2026 | Routine annual director compensation grant; not a market signal |
Hinman, Jacqueline C. | Director | Stock Award (Compensation) | 5,298 shares | May 12, 2026 | Routine annual director compensation grant; not a market signal |
Lewis, Clinton A. Jr. | Director | RSU Award (Compensation) | 10,809 RSUs | May 12, 2026 | Routine annual director compensation grant; not a market signal |
Robbie, David A. | Director | Stock Award + Tax Withholding Sale | 5,298 shares awarded; 1,233 shares withheld for taxes | May 12, 2026 | Routine compensation; tax withholding sale is obligation-driven, not discretionary |
Sullivan, Kathryn D. | Director | Stock Award (Compensation) | 7,901 shares | May 12, 2026 | Routine annual director compensation grant; retiring end of 2026 |
Tozier, Scott | Director | RSU Award (Compensation) | 5,298 RSUs | May 12, 2026 | Routine annual director compensation grant; separate from May 1 open-market buy |
Vincent, Anton V. | Director | RSU Award (Compensation) | 10,203 RSUs | May 12, 2026 | Routine annual director compensation grant; not a market signal |
Source: SEC Form 4 filings. No open-market sales by executives or directors since the Q1 print. The sole discretionary open-market buy — Director Scott Tozier’s 10,000-share purchase on May 1 at the post-Q1 lows — is a constructive signal. No 10b5-1 plan initiations or Form 144 filings were identified in the period. The absence of executive (CEO/CFO) open-market transactions is notable but not unusual given the transformation/separation process and associated blackout periods.